EBV-positive diffuse large B-cell lymphoma in people with weakened immune systems
EBV-Positive Diffuse Large B-cell Lymphoma: Defining Biologic Determinants of Disease Pathogenesis in Immunodeficiency
Researchers will compare tumor and virus features in people with EBV-positive diffuse large B-cell lymphoma who have weakened immune systems from HIV or medical treatments to better link biology to health outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Vermont & St Agric College NIH-funded |
| Lab location | 1 site (Burlington, United States) |
| Project ID | NIH-11222776 on NIH RePORTER |
What this research studies
You or patients like you would have tumor samples and medical records analyzed from groups in sub-Saharan Africa and the United States. The team will determine whether Epstein-Barr virus is active in the tumors and identify viral latency patterns, then perform detailed molecular profiling of the tumor and virus. They will link those biological findings to immune status (for example HIV or treatment-related immunodeficiency) and to clinical outcomes. The overall aim is to improve diagnosis and point toward potential targets for new treatments.
Who could benefit from this research
Good fit: Ideal candidates are people diagnosed with diffuse large B-cell lymphoma whose tumors test positive for Epstein-Barr virus, especially those with HIV or iatrogenic immunodeficiency, from cohorts in sub-Saharan Africa or the United States.
Not a fit: People without EBV-positive DLBCL, those with unrelated cancers, or anyone who cannot provide tumor samples or medical data are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could improve how EBV-positive DLBCL is diagnosed and point to new targeted therapies for people with immunodeficiency.
How similar studies have performed: Prior studies in Western populations show EBV-positive DLBCL often has worse outcomes, but comprehensive global molecular profiling in different immunodeficiency settings is relatively new.
Where this research is happening
Burlington, United States
- University of Vermont & St Agric College — Burlington, United States (Active)
Researchers
- Principal investigator: Volaric, Ashley Keller — University of Vermont & St Agric College
- Study coordinator: Volaric, Ashley Keller
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.